Macrophage-cancer hybrid membrane-coated nanoparticles for targeting lung metastasis in breast cancer therapy

• Published in: Journal of nanobiotechnology 2020-06, Vol.18 (1), p.92-17, Article 92
• Main Authors: Gong, Chunai, Yu, Xiaoyan, You, Benming, Wu, Yan, Wang, Rong, Han, Lu, Wang, Yujie, Gao, Shen, Yuan, Yongfang
• Format: Article
• Language: English
• Subjects: Animals; Anthracyclines; Antineoplastic Agents - chemistry; Antineoplastic Agents - pharmacokinetics; Antineoplastic Agents - pharmacology; Antineoplastic Agents - therapeutic use; Biomimetic Materials - chemistry; Biomimetic nanoparticles; Biomimetics; Breast cancer; Breast Neoplasms - pathology; Cancer metastasis; Cancer therapies; Cell adhesion & migration; Cell Line, Tumor; Cell Membrane - chemistry; Cell membranes; Cell Proliferation - drug effects; Chemotherapy; Coatings; Doxorubicin; Doxorubicin - chemistry; Doxorubicin - pharmacokinetics; Doxorubicin - pharmacology; Doxorubicin - therapeutic use; Drug delivery systems; Efficiency; Female; Glycolic acid; Health aspects; Hemodialysis; Hybrid membrane; Laboratory animals; Lung cancer; Lung Neoplasms - drug therapy; Lung Neoplasms - secondary; Lungs; Macrophages; Macrophages - cytology; Mammary Neoplasms, Experimental; Membranes; Metastases; Metastasis; Metastasis breast cancer; Mice; Multi-target capability; Nanoparticles; Nanoparticles - chemistry; Nanoparticles - metabolism; Nanoparticles - therapeutic use; Particle size; Penicillin; Polylactide-co-glycolide; Proteins; RAW 264.7 Cells; Tumors
• ISSN: 1477-3155; 1477-3155
• DOI: 10.1186/s12951-020-00649-8

Cell membrane- covered drug-delivery nanoplatforms have been garnering attention because of their enhanced bio-interfacing capabilities that originate from source cells. In this top-down technique, nanoparticles (NPs) are covered by various membrane coatings, including membranes from specialized cells or hybrid membranes that combine the capacities of different types of cell membranes. Here, hybrid membrane-coated doxorubicin (Dox)-loaded poly(lactic-co-glycolic acid) (PLGA) NPs (DPLGA@[RAW-4T1] NPs) were fabricated by fusing membrane components derived from RAW264.7(RAW) and 4T1 cells (4T1). These NPs were used to treat lung metastases originating from breast cancer. This study indicates that the coupling of NPs with a hybrid membrane derived from macrophage and cancer cells has several advantages, such as the tendency to accumulate at sites of inflammation, ability to target specific metastasis, homogenous tumor targeting abilities in vitro, and markedly enhanced multi-target capability in a lung metastasis model in vivo. The DPLGA@[RAW-4T1] NPs exhibited excellent chemotherapeutic potential with approximately 88.9% anti-metastasis efficacy following treatment of breast cancer-derived lung metastases. These NPs were robust and displayed the multi-targeting abilities of hybrid membranes. This study provides a promising biomimetic nanoplatform for effective treatment of breast cancer metastasis.